Zgony i powikłania sercowo-naczyniowe cukrzycy a stosowane leki doustne – rejestr wszystkich mieszkańców Danii, u których rozpoczęto leczenie w latach 1997-2006

Tina Ken Schramm wsp – Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study Eur Heart J first published online April 6, 2011

Conclusion: Monotherapy with the most used ISs, including glimepiride, glibenclamide, glipizide, and tolbutamide, seems to be associated with increased mortality and cardiovascular risk compared with metformin. Gliclazide and repaglinide appear to be associated with a lower risk than other ISs.

Opracowane na podstawie: Eur Heart Jfirst published online April 6, 2011/ 6 kwietnia 2011

Dodaj komentarz